PEGS Europe Tablet Banner

Cambridge Healthtech Institute’s 3rd Annual
Protein Aggregates & Particles

Understanding Aggregation Kinetics to Effect Control and Minimise Immunogenicity Risks

3 - 4 November 2016 | EPIC SANA Lisboa Hotel | Lisboa PORTUGAL


Aggregation impacts biopharmaceutical development at every stage from discovery to development to processing. The mechanisms and kinetics of aggregation, particularly of the novel and complex biomolecules, are not well-defined, thus regulators are highly concerned about its impact on drug product safety and immunogenicity. As such, companies are expending all efforts to predict, identify, characterize, control and minimize the occurrence of aggregates and particles.

The 3rd Annual Protein Aggregates & Particles conference will bring together protein chemists and biochemists, analytical scientists and engineers to uncover the underlying mechanisms of aggregation, predict aggregation propensity using in silico and modeling tools, design and engineer novel biomolecules with reduced aggregation, as well as formulate drug products to minimize aggregates and particulates.

Preliminary Agenda


MECHANISMS AND KINETICS OF AGGREGATION

Keynote Presentation:
Impact of Non-Proteinaceous Particles on the Characterization and Formation of Protein Particles

Wim Jiskoot, Ph.D., Professor, Gorlaeus Laboratories, Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR)

Mechanisms of Protein Aggregation

Thomas Laue, Ph.D., Professor, Molecular, Cellular & Biomedical Sciences, University of New Hampshire

Elucidation of Aggregation Mechanisms in Therapeutic Protein, and Prediction of Formulation Strategies

Paul Dalby, Ph.D., Professor, Biochemical Engineering, University College London


AGGREGATION PROPENSITY AND ENHANCING AGGREGATION-RESISTANCE

Relationship between Aggregate Propensity and Biophysical Parameters of Proteins in Solution

Susumu Uchiyama, Ph.D., Associate Professor, Biotechnology, Osaka University

Predicting Solubility Changes upon Mutations and Inhibiting Disease-Related Aggregation (tentative)

Pietro Sormanni, Post-Doc Researcher, Chemistry, University of Cambridge


PARTICLE ANALYSIS AND CHARACTERIZATION – DETECTION, IDENTIFICATION, CHARACTERIZATION AND CONTROL

Comparisons between Particle Identification Techniques

Jonas Hoeg Thygesen, Ph.D., Research Scientist, R&D, Microanalysis Centre, Novo Nordisk Pharmatech A/S

Identification and a Discriminant Analysis of Sub-Visible (Protein and Non-Proteinaceous) Particles

Zahir Akhunzada, Ph.D., Research Scientist, ABD Process Development, Bristol-Myers Squibb

Microscopy-Based Particle Counting and Characterization in a High-Throughput Formulation Screening Platform

Christian Ried, Ph.D., Senior Scientist, NBE Formulation Sciences & Process Development, AbbVie Deutschland GmbH & Co., KG


CORRELATION BETWEEN AGGREGATION, STRUCTURE, STABILITY AND IMMUNOGENICITY

Keynote Presentation:
Using Denaturant Solutions to Probe the Colloidal Stability of Partially Folded Proteins and the Link to Aggregation

Robin Curtis, Ph.D., University of Manchester

Understanding the Relationship between Aggregation and Immunogenicity of Biotherapeutic Proteins

Jeremy Derrick, Ph.D., Professor, Molecular Microbiology, University of Manchester

Viscosity-Derived Parameters and Thermal Solution Properties of Bi-Specific Dual Variable Domain Immunoglobulins

Peter M. Ihnat, Ph.D., Principal Research Scientist, Drug Product Development Pre-Formulations, AbbVie Bioresearch Center




For more details on the conference, please contact:
Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
T: +1 781.972.5439
E: mlangley@healthtech.com

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Jason Gerardi
Business Development Manager
(+1) 781-972-5452
jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
(+1) 781-972-5471
dinerstein@healthtech.com